ReviewResearch (Washington, D.C.)2026
Benign Uroandrological Ecosystem: A Thorough Overview from Single-Cell and Spatial Transcriptomics.
Review in Research (Washington, D.C.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Benign urological and andrological diseases (BUADs) represent common yet complex clinical challenges, where the diversity and dynamic nature of their microenvironments substantially influence disease onset and progression. In recent years, the emergence of single-cell RNA sequencing (scRNA-seq) and spatially resolved transcriptomic (SRT) technologies has provided unprecedented insights into the cellular heterogeneity and spatiotemporal architecture of these disease microenvironments. This review outlines current applications of scRNA-seq and SRT in BUADs, with a focus on their utility in mapping cell-cell interactions, uncovering pathological mechanisms, and prioritizing therapeutic targets. Across the upper urinary tract, prostate, bladder, urethra, and male reproductive organs, single-cell analyses reveal that parenchymal cell dysfunction and microenvironmental remodeling are the core pathological processes of disease progression. This review also discusses the limitations of scRNA-seq/SRT and the existing challenges of current research methods and paradigms in BUADs and outlines future research directions and integrative strategies to facilitate clinical translation and precision medicine. Collectively, these up-to-date findings not only deepen the understanding of the microenvironment in BUADs but also provide a scientific foundation for the development of novel therapeutic strategies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.